Impact of an oral gonadotropin-releasing hormone antagonist on severe ovarian hyperstimulation syndrome in a patient with breast cancer who received a sustained-release gonadotropin-releasing hormone agonist: A case report

J Obstet Gynaecol Res. 2021 Dec;47(12):4472-4477. doi: 10.1111/jog.15059. Epub 2021 Oct 12.

Abstract

Postoperative hormone therapy for hormone-sensitive patients with breast cancer is important to prevent a recurrence. As hormone therapy does not induce infertility in patients, fertility-preserving therapy is not provided during treatment. Here, however, we performed controlled ovarian stimulation and embryo freezing for fertility preservation under the influence of a sustained-release gonadotropin-releasing hormone agonist in a patient with breast cancer whose postoperative treatment plan was changed from hormone therapy to chemotherapy. After oocyte retrieval, the patient developed treatment-resistant severe symptomatic ovarian hyperstimulation syndrome. Following treatment with oral gonadotropin-releasing hormone antagonist, her symptoms immediately improved, and she could receive chemotherapy on schedule.

Keywords: breast cancer; gonadotropin-releasing hormone agonist; gonadotropin-releasing hormone antagonist; oncofertility; ovarian hyperstimulation syndrome.

Publication types

  • Case Reports

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Delayed-Action Preparations
  • Female
  • Fertilization in Vitro
  • Gonadotropin-Releasing Hormone*
  • Humans
  • Ovarian Hyperstimulation Syndrome* / chemically induced
  • Ovulation Induction

Substances

  • Delayed-Action Preparations
  • Gonadotropin-Releasing Hormone